IL156408A0 - Pyrazole derivatives and pharmaceutical compositions containing the same - Google Patents
Pyrazole derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL156408A0 IL156408A0 IL15640801A IL15640801A IL156408A0 IL 156408 A0 IL156408 A0 IL 156408A0 IL 15640801 A IL15640801 A IL 15640801A IL 15640801 A IL15640801 A IL 15640801A IL 156408 A0 IL156408 A0 IL 156408A0
- Authority
- IL
- Israel
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- pyrazole derivatives
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25788700P | 2000-12-21 | 2000-12-21 | |
US28694901P | 2001-04-27 | 2001-04-27 | |
PCT/US2001/050312 WO2002068415A1 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL156408A0 true IL156408A0 (en) | 2004-01-04 |
Family
ID=26946273
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15636801A IL156368A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15640701A IL156407A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15640801A IL156408A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15638901A IL156389A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15636901A IL156369A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL156369A IL156369A (en) | 2000-12-21 | 2003-06-10 | History of pyrazole and pharmaceutical preparations containing them |
IL156389A IL156389A (en) | 2000-12-21 | 2003-06-11 | History of pyrazole and pharmaceutical preparations containing them |
IL209827A IL209827A0 (en) | 2000-12-21 | 2010-12-07 | A process for preparing pyrazole derivatives |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15636801A IL156368A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15640701A IL156407A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15638901A IL156389A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15636901A IL156369A0 (en) | 2000-12-21 | 2001-12-19 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL156369A IL156369A (en) | 2000-12-21 | 2003-06-10 | History of pyrazole and pharmaceutical preparations containing them |
IL156389A IL156389A (en) | 2000-12-21 | 2003-06-11 | History of pyrazole and pharmaceutical preparations containing them |
IL209827A IL209827A0 (en) | 2000-12-21 | 2010-12-07 | A process for preparing pyrazole derivatives |
Country Status (28)
Country | Link |
---|---|
US (16) | US20030105090A1 (xx) |
EP (10) | EP2264028A1 (xx) |
JP (19) | JP2004518743A (xx) |
KR (8) | KR100875091B1 (xx) |
CN (6) | CN100436452C (xx) |
AP (2) | AP1588A (xx) |
AR (4) | AR042169A1 (xx) |
AT (9) | ATE354573T1 (xx) |
AU (7) | AU2001297619B2 (xx) |
BR (2) | BR0116493A (xx) |
CA (8) | CA2432799C (xx) |
CY (1) | CY1106297T1 (xx) |
DE (8) | DE60119775T2 (xx) |
DK (3) | DK1353916T3 (xx) |
ES (7) | ES2272567T3 (xx) |
HK (8) | HK1059776A1 (xx) |
HU (5) | HUP0400908A3 (xx) |
IL (8) | IL156368A0 (xx) |
MX (8) | MXPA03005610A (xx) |
MY (1) | MY140377A (xx) |
NO (5) | NO328537B1 (xx) |
NZ (8) | NZ526468A (xx) |
PL (2) | PL210066B1 (xx) |
PT (3) | PT1345922E (xx) |
RU (1) | RU2355688C2 (xx) |
SI (2) | SI1353916T1 (xx) |
TW (2) | TWI290551B (xx) |
WO (8) | WO2002057259A2 (xx) |
Families Citing this family (370)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982260B1 (en) | 1999-11-22 | 2006-01-03 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022603A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ES2307667T3 (es) * | 2000-12-05 | 2008-12-01 | Vertex Pharmaceuticals Incorporated | Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas. |
PT1345922E (pt) | 2000-12-21 | 2006-09-29 | Vertex Pharma | Compostos de pirazole uteis como inibidores de proteina-quinase |
US20030125344A1 (en) * | 2001-03-23 | 2003-07-03 | Bayer Corporation | Rho-kinase inhibitors |
US7034026B2 (en) | 2001-04-10 | 2006-04-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
US7138404B2 (en) * | 2001-05-23 | 2006-11-21 | Hoffmann-La Roche Inc. | 4-aminopyrimidine derivatives |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
JP4542338B2 (ja) | 2001-09-26 | 2010-09-15 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物 |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
DE60325551D1 (de) | 2002-01-10 | 2009-02-12 | Hoffmann La Roche | Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CA2475633C (en) * | 2002-02-06 | 2013-04-02 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
EP1485380B1 (en) * | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
US7179826B2 (en) | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
AU2003220299A1 (en) * | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
CA2480800C (en) | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity |
JPWO2003104230A1 (ja) | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
JP2005536517A (ja) * | 2002-07-23 | 2005-12-02 | スミスクライン ビーチャム コーポレーション | キナーゼインヒビターとしてのピラゾロピリミジン |
NZ537752A (en) | 2002-07-29 | 2006-12-22 | Rigel Pharmaceuticals Inc | Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases |
CN1319968C (zh) | 2002-08-02 | 2007-06-06 | 沃泰克斯药物股份有限公司 | 用作gsk-3的抑制剂的吡唑组合物 |
SI1532145T1 (sl) * | 2002-08-02 | 2007-02-28 | Vertex Pharma | Pirazolni sestavki, koristni kot inhibitorji GSK-3 |
FR2844267B1 (fr) * | 2002-09-05 | 2008-02-15 | Aventis Pharma Sa | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
KR101166745B1 (ko) | 2002-09-05 | 2012-07-23 | 아방티 파르마 소시에테 아노님 | 의약으로서의 신규한 아미노인다졸 유도체 및 이를 함유하는 약제학적 조성물 |
AU2003255482A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
KR101122782B1 (ko) * | 2002-10-04 | 2012-04-12 | 프라나 바이오테크놀로지 리미티드 | 신경 활성 화합물 |
KR100490893B1 (ko) * | 2002-10-11 | 2005-05-23 | (주) 비엔씨바이오팜 | 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물 |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
US7462613B2 (en) | 2002-11-19 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
FR2847253B1 (fr) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
US7309701B2 (en) | 2002-11-19 | 2007-12-18 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
EA013811B1 (ru) * | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
EP1644338A1 (en) * | 2003-04-01 | 2006-04-12 | Aponetics AG | 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases |
ES2308182T3 (es) * | 2003-06-02 | 2008-12-01 | Astrazeneca Ab | Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer. |
JP4869068B2 (ja) | 2003-06-19 | 2012-02-01 | スミスクライン ビーチャム コーポレーション | 化合物 |
KR101218213B1 (ko) * | 2003-07-03 | 2013-01-04 | 시토비아 인크. | 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린 |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
JP2007500179A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | キナーゼ阻害剤としての2−アミノフェニル−4−フェニルピリミジン |
KR101201603B1 (ko) | 2003-07-30 | 2012-11-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물 |
US20060024690A1 (en) * | 2003-09-19 | 2006-02-02 | Kao H P | Normalization of data using controls |
US20050221357A1 (en) * | 2003-09-19 | 2005-10-06 | Mark Shannon | Normalization of gene expression data |
US7417726B2 (en) * | 2003-09-19 | 2008-08-26 | Applied Biosystems Inc. | Normalization of data using controls |
WO2005030131A2 (en) * | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Bis-quinazoline compounds for the treatment of bacterial infections |
AU2004283137A1 (en) | 2003-10-17 | 2005-05-06 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
WO2005056547A2 (en) * | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
EP1709045A1 (en) * | 2003-12-09 | 2006-10-11 | Vertex Pharmaceuticals Incorporated | Naphthyridine derivatives and their use as modulators of muscarinic receptors |
EP1694686A1 (en) * | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
CA2556239A1 (en) | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US20080050314A1 (en) * | 2004-02-26 | 2008-02-28 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b) |
US7786165B2 (en) * | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
EP2522670A1 (en) * | 2004-04-07 | 2012-11-14 | Takeda Pharmaceutical Company Limited | Heterocyclic CRF receptor antagonists |
WO2005103010A2 (en) * | 2004-04-21 | 2005-11-03 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
ES2505090T3 (es) * | 2004-05-07 | 2014-10-09 | Amgen Inc. | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
ES2540987T3 (es) | 2004-05-14 | 2015-07-15 | Millennium Pharmaceuticals, Inc. | Métodos para preparar inhibidores de la aurora cinasa |
SI1771450T1 (sl) * | 2004-05-14 | 2008-06-30 | Millennium Pharm Inc | Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora |
US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
AU2012200416B2 (en) * | 2004-05-14 | 2014-07-31 | Millennium Pharmaceuticals, Inc. | "Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase" |
CA2566444A1 (en) * | 2004-05-14 | 2005-12-01 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
US20080009531A1 (en) * | 2004-05-20 | 2008-01-10 | Bayer Pharmaceuticals Corporation | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes |
KR20070034519A (ko) * | 2004-05-27 | 2007-03-28 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 광감성 중합체 보호층용 현상제 |
WO2006007532A2 (en) * | 2004-07-01 | 2006-01-19 | Synta Pharmaceuticals Corp. | 2-substituted heteroaryl compounds |
CN101031551A (zh) * | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | 针对癌症治疗的肝细胞生长因子/c-met活性的喹唑啉调节剂 |
EP1778669A2 (en) * | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
AR050948A1 (es) * | 2004-09-24 | 2006-12-06 | Hoffmann La Roche | Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer. |
ATE542802T1 (de) * | 2004-09-30 | 2012-02-15 | Tibotec Pharm Ltd | Hiv-inhibierende 5-substituierte pyrimidine |
WO2006035067A2 (en) * | 2004-09-30 | 2006-04-06 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-heterocyclyl pyrimidines |
KR20070057798A (ko) * | 2004-09-30 | 2007-06-07 | 티보텍 파마슈티칼즈 리미티드 | Hiv를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘 |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
EP1828165B1 (en) * | 2004-10-29 | 2013-03-20 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
JP2008519034A (ja) | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
CA2587427A1 (en) * | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
KR101334511B1 (ko) * | 2004-12-30 | 2013-11-29 | 아스텍스 테라퓨틱스 리미티드 | Cdk, gsk 및 오로라 키나아제의 활성을 조절하는피라졸 화합물 |
EP1841760B1 (en) | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
WO2006081230A2 (en) * | 2005-01-26 | 2006-08-03 | Schering Corporation | 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer |
ES2555063T3 (es) * | 2005-02-04 | 2015-12-28 | Astrazeneca Ab | Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas |
PT1853602E (pt) * | 2005-02-16 | 2010-08-25 | Astrazeneca Ab | Compostos químicos |
BRPI0607455A2 (pt) * | 2005-02-16 | 2009-09-01 | Astrazeneca Ab | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica |
CN101500574A (zh) * | 2005-03-15 | 2009-08-05 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
WO2006100461A1 (en) * | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
CA2602372A1 (en) * | 2005-04-05 | 2006-10-12 | Astrazeneca Ab | Pyrimidine derivatives for use as anticancer agents |
GB0507347D0 (en) * | 2005-04-12 | 2005-05-18 | Astrazeneca Ab | Chemical compounds |
AU2006233537A1 (en) | 2005-04-14 | 2006-10-19 | F. Hoffmann-La Roche Ag | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
EP1877057A1 (en) * | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
EP1876178B1 (en) * | 2005-04-28 | 2015-05-27 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and use thereof as medicine |
US7745451B2 (en) | 2005-05-04 | 2010-06-29 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions |
EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
US20080194606A1 (en) * | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
MX2007014328A (es) * | 2005-05-16 | 2008-02-12 | Astrazeneca Ab | Compuestos quimicos. |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
NZ564222A (en) | 2005-06-14 | 2011-10-28 | Taigen Biotechnology Co Ltd | Pyrimidine compounds |
EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
AU2006279376B2 (en) * | 2005-08-18 | 2011-04-14 | Vertex Pharmaceuticals Incoporated | Pyrazine kinase inhibitors |
WO2007023382A2 (en) * | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
KR20140025610A (ko) * | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
UA96427C2 (xx) * | 2005-09-30 | 2011-11-10 | Мийкана Терапьютикс, Инк. | Заміщені сполуки піразолу[замещенные соединения пиразола |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
AU2006307657B2 (en) * | 2005-10-28 | 2010-10-28 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス,インコーポレイティド | 神経発生のgaba受容体媒介調節 |
ES2372540T3 (es) * | 2005-11-01 | 2012-01-23 | Array Biopharma, Inc. | Activadores de glucocinasa. |
MX2008005717A (es) * | 2005-11-03 | 2008-10-15 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de la cinasa. |
WO2007059299A1 (en) * | 2005-11-16 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
WO2007077435A1 (en) | 2005-12-30 | 2007-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007081978A2 (en) * | 2006-01-11 | 2007-07-19 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor / c-met activity |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101415674A (zh) * | 2006-02-16 | 2009-04-22 | 先灵公司 | 作为erk抑制剂的吡咯烷衍生物 |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
DK2004632T3 (da) | 2006-03-30 | 2014-06-16 | Janssen R & D Ireland | Hiv-inhiberende 5-amidosubstituerede pyrimidiner |
JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
KR20090023561A (ko) | 2006-04-07 | 2009-03-05 | 노파르티스 아게 | a) 피리미딜아미노벤즈아미드 화합물과 b) Thr315Ile 키나제 억제제를 포함하는 조합물 |
CA2683756A1 (en) | 2006-04-14 | 2007-10-25 | Prana Biotechnology Limited | Method of treatment of age-related macular degeneration(amd) |
WO2007126126A1 (ja) * | 2006-04-27 | 2007-11-08 | Banyu Pharmaceutical Co., Ltd. | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
PE20080993A1 (es) | 2006-06-27 | 2008-10-06 | Takeda Pharmaceutical | Compuestos ciclicos fusionados como moduladores del receptor gpr40 |
EP2049119A2 (en) | 2006-06-29 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20090209537A1 (en) * | 2006-06-30 | 2009-08-20 | Kyowa Hakko Kirin Co., Ltd. | Aurora inhibitors |
JP2009541480A (ja) * | 2006-06-30 | 2009-11-26 | アストラゼネカ アクチボラグ | 癌の治療において有用なピリミジン誘導体 |
EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
JP2010500352A (ja) * | 2006-08-09 | 2010-01-07 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法 |
US7744164B2 (en) * | 2006-08-11 | 2010-06-29 | Schluimberger Technology Corporation | Shield of a degradation assembly |
JP2008081492A (ja) * | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
WO2008053812A1 (fr) * | 2006-10-27 | 2008-05-08 | Mitsubishi Tanabe Pharma Corporation | Dérivé de cyanopyridine et son utilisation médicale |
NZ576750A (en) * | 2006-11-02 | 2012-01-12 | Vertex Pharma | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
EP2099787B1 (en) * | 2006-12-19 | 2010-07-21 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines useful as inhibitors of protein kinases |
KR20090094073A (ko) * | 2006-12-29 | 2009-09-03 | 티보텍 파마슈티칼즈 리미티드 | Hiv를 억제하는 6-치환된 피리미딘 |
CN106045965A (zh) * | 2006-12-29 | 2016-10-26 | 爱尔兰詹森科学公司 | 抑制hiv的5,6‑取代的嘧啶类化合物 |
ATE551334T1 (de) | 2007-02-06 | 2012-04-15 | Novartis Ag | Pi3-kinase-hemmer und verfahren zu ihrer verwendung |
US20100104567A1 (en) | 2007-03-05 | 2010-04-29 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
AU2008226466B2 (en) * | 2007-03-09 | 2013-06-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
JP5520057B2 (ja) * | 2007-03-09 | 2014-06-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
AU2008226461A1 (en) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
CA2682195A1 (en) * | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CN101679429A (zh) * | 2007-04-18 | 2010-03-24 | 阿斯利康(瑞典)有限公司 | 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途 |
JP4782239B2 (ja) | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
NZ580884A (en) | 2007-05-02 | 2012-02-24 | Vertex Pharma | Thiazoles and pyrazoles useful as kinase inhibitors |
CA2694381A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2008137622A2 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
EP2152702B1 (en) * | 2007-05-04 | 2011-08-24 | AstraZeneca AB | Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer |
UA99459C2 (xx) | 2007-05-04 | 2012-08-27 | Астразенека Аб | ПОХІДНІ 9-(ПІРАЗОЛ-3-ІЛ)-9H-ПУРИН-2-АМІНУ І 3-(ПІРАЗОЛ-3-ІЛ)-3H-ІМІДАЗО$4,5-b]ПІРИДИН-5-АМІНУ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ РАКУ$ПРОИЗВОДНЫЕ 9-(ПИРАЗОЛ-3-ИЛ)-9H-ПУРИН-2-АМИНА И 3-(ПИРАЗОЛ-3-ИЛ)-3H-ИМИДАЗО$4,5-b]ПИРИДИН-5-АМИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА |
JP2010528021A (ja) * | 2007-05-24 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール |
KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
US20090029992A1 (en) * | 2007-06-11 | 2009-01-29 | Agoston Gregory E | Substituted pyrazole compounds |
JP2010532756A (ja) * | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | mTORC1及びmTORC2の両方の阻害剤を含む組み合わせ抗癌療法 |
WO2009007753A2 (en) * | 2007-07-11 | 2009-01-15 | Astrazeneca Ab | 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer |
AU2008279097B2 (en) * | 2007-07-25 | 2013-05-02 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
WO2009013545A2 (en) * | 2007-07-26 | 2009-01-29 | Astrazeneca Ab | Chemical compounds |
CN101790532B (zh) | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3,4-b]吡啶-3-胺及其衍生物的制备方法 |
TW200906818A (en) * | 2007-07-31 | 2009-02-16 | Astrazeneca Ab | Chemical compounds |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009027736A2 (en) * | 2007-08-27 | 2009-03-05 | Astrazeneca Ab | 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer |
MX2010002772A (es) | 2007-09-21 | 2010-03-31 | Array Biopharma Inc | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus. |
EP2214487B1 (en) | 2007-10-11 | 2013-11-27 | GlaxoSmithKline LLC | Novel seh inhibitors and their use |
WO2009078999A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
US20090270418A1 (en) * | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
NZ587504A (en) | 2008-02-21 | 2012-09-28 | Merck Sharp & Dohme | Benzopyrazole derivatives as ERK inhibitors |
US8519136B2 (en) | 2008-02-22 | 2013-08-27 | Msd K.K. | Aminopyridine derivatives having aurora a selective inhibitory action |
WO2009131598A1 (en) | 2008-04-21 | 2009-10-29 | Taigen Biotechnology Co., Ltd. | Heterocyclic compounds |
WO2010011411A1 (en) | 2008-05-27 | 2010-01-28 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and media for detecting network anomalies |
BRPI0915101A2 (pt) * | 2008-06-11 | 2017-03-21 | Astrazeneca Ab | composto, uso do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
KR20110046514A (ko) * | 2008-07-31 | 2011-05-04 | 제넨테크, 인크. | 피리미딘 화합물, 조성물 및 사용 방법 |
KR20110050549A (ko) * | 2008-09-03 | 2011-05-13 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 이를 포함하는 제약 제제 |
WO2010028236A1 (en) * | 2008-09-05 | 2010-03-11 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
CN102264728B (zh) * | 2008-09-15 | 2015-02-04 | 加利福尼亚大学董事会 | 用于调节ire1、src和abl活性的方法和组合物 |
RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
US9023834B2 (en) | 2008-11-13 | 2015-05-05 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
PA8851101A1 (es) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
EP2373664B1 (en) | 2008-12-19 | 2013-06-12 | Nerviano Medical Sciences S.r.l. | Bicyclic pyrazoles as protein kinase inhibitors |
WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
US8809343B2 (en) | 2008-12-26 | 2014-08-19 | Fudan University | Pyrimidine derivative, preparation method and use thereof |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
BRPI1013347A2 (pt) * | 2009-02-27 | 2016-03-29 | Ambit Biosciences Corp | derivados de quinazolina modulantes da quinase jak e métodos para o uso dos mesmos |
CA2660962A1 (en) | 2009-03-31 | 2010-09-30 | Astellas Pharma Inc. | Novel pharmaceutical composition for treatment of schizophrenia |
US8399663B2 (en) | 2009-04-03 | 2013-03-19 | Astellas Pharma Inc. | Salt of 1,3,5-triazine-2,4,6-triamine derivative |
JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
WO2010144338A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
CA2764823A1 (en) * | 2009-06-08 | 2010-12-16 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
CN102573481A (zh) * | 2009-06-09 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 脲基苯基取代的三嗪衍生物及其治疗应用 |
EP2440057A4 (en) | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
BRPI1011319A2 (pt) * | 2009-06-09 | 2016-06-21 | California Capital Equity Llc | derivados de triazina benzil-substituídos e suas aplicações terapêuticas |
AU2010258993B2 (en) * | 2009-06-09 | 2014-07-31 | Nantbio, Inc. | Styryl-triazine derivatives and their therapeutical applications |
CA2763730A1 (en) * | 2009-06-18 | 2010-12-23 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
TWI468402B (zh) * | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
PT2470552E (pt) | 2009-08-26 | 2014-01-30 | Sanofi Sa | Novos hidratos de fluoroglicósido heteroaromáticos cristalinos, fármacos compreendendo estes compostos e sua utilização |
NZ620174A (en) * | 2009-09-16 | 2016-08-26 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
KR101764780B1 (ko) * | 2009-11-13 | 2017-08-03 | 인튜어티브 서지컬 오퍼레이션즈 인코포레이티드 | 여분의 닫힘 메커니즘을 구비한 단부 작동기 |
EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
RU2012132473A (ru) | 2009-12-30 | 2014-02-10 | Селджин Авиломикс,Инк | Лиганд-направленная ковалентная модификация белка |
SA111320200B1 (ar) * | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
US8653064B2 (en) | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20130059830A1 (en) * | 2010-05-20 | 2013-03-07 | Fa-Xiang Ding | Novel prolylcarboxypeptidase inhibitors |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
KR101531448B1 (ko) | 2010-06-04 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서의 아미노피리미딘 유도체 |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
SI2598482T1 (sl) | 2010-07-29 | 2018-09-28 | Oryzon Genomics, S.A. | Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba |
US20130225614A1 (en) * | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
CA2809993A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
US8633207B2 (en) | 2010-09-01 | 2014-01-21 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
WO2012030910A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
US8633209B2 (en) | 2010-09-01 | 2014-01-21 | Ambit Biosciences Corporation | Hydrobromide salts of a pyrazolylaminoquinazoline |
EP2611502A1 (en) * | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Adenosine a3 receptor modulating compounds and methods of use thereof |
WO2012030944A2 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Quinoline and isoquinoline compounds and methods of use thereof |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
US8815882B2 (en) | 2010-11-10 | 2014-08-26 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
KR20140006048A (ko) | 2011-03-24 | 2014-01-15 | 케밀리아 에이비 | 신규한 피리미딘 유도체 |
JP2014524456A (ja) * | 2011-08-25 | 2014-09-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン/スレオニンpak1阻害剤 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
ES2575710T3 (es) * | 2011-09-22 | 2016-06-30 | Pfizer Inc | Derivados de pirrolopirimidina y purina |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CA2849995A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
WO2013092940A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | 2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors |
US9447051B2 (en) * | 2012-02-17 | 2016-09-20 | Abbvie Inc. | Diaminopyrimidines and uses thereof |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
EP2852586A1 (en) | 2012-03-16 | 2015-04-01 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
KR102089239B1 (ko) | 2012-04-24 | 2020-03-16 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제 |
AU2013265307B2 (en) * | 2012-05-24 | 2016-04-07 | Cellzome Limited | Heterocyclyl pyrimidine analogues as TYK2 inhibitors |
MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
AU2013289615B2 (en) * | 2012-07-10 | 2017-06-08 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
MY183976A (en) * | 2012-09-19 | 2021-03-17 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition for oral administration with improved dissolution and/or absorption |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
CN103059002B (zh) * | 2012-12-31 | 2015-04-22 | 中山大学 | 具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用 |
CN103191120B (zh) * | 2012-12-31 | 2015-11-25 | 刘强 | 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途 |
CN103202843B (zh) * | 2012-12-31 | 2015-04-29 | 刘强 | 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途 |
CN103910716A (zh) * | 2013-01-07 | 2014-07-09 | 华东理工大学 | 2,4-二取代-环烷基[d]嘧啶类化合物及其用途 |
EP3527563B1 (en) | 2013-03-12 | 2021-09-01 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
CA2903979A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
WO2014145485A2 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Map kinase modulators and uses thereof |
CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
WO2015003355A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
WO2015028848A1 (en) * | 2013-09-02 | 2015-03-05 | Piramal Enterprises Limited | Bicyclic heterocyclic compounds as multi-kinase inhibitors |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
ES2705342T3 (es) | 2013-10-17 | 2019-03-22 | Vertex Pharma | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
LT3089971T (lt) | 2014-01-01 | 2020-10-12 | Medivation Technologies Llc | Junginiai ir panaudojimo būdai |
DK3777833T3 (da) | 2014-03-13 | 2023-12-18 | Neuroderm Ltd | Dopa-decarboxylase-inhibitorsammensætninger |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
MX2016012574A (es) | 2014-03-28 | 2017-09-26 | Calitor Sciences Llc | Compuestos heteroarilo sustituidos y metodos de uso. |
KR20160140892A (ko) | 2014-04-04 | 2016-12-07 | 아이오메트 파마 엘티디 | 의약에 사용하기 위한 인돌 유도체 |
US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
CN105367555B (zh) * | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
EA032473B1 (ru) | 2014-12-23 | 2019-05-31 | Аксикин Фармасьютикалз, Инк. | 3,5-диаминопиразоловые ингибиторы киназы |
WO2016123627A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
EP3283482B1 (en) | 2015-04-17 | 2022-04-06 | Ludwig Institute for Cancer Research Ltd | Plk4 inhibitors |
EA032953B1 (ru) | 2015-05-28 | 2019-08-30 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Нафтиридиновые соединения в качестве ингибиторов jak киназы |
JP2018135268A (ja) * | 2015-06-05 | 2018-08-30 | 大日本住友製薬株式会社 | 新規ヘテロアリールアミノ−3−ピラゾール誘導体およびその薬理学上許容される塩 |
WO2017015316A1 (en) | 2015-07-21 | 2017-01-26 | Millennium Pharmaceuticals, Inc. | Administration of aurora kinase inhibitor and chemotherapeutic agents |
EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
JP2019500352A (ja) | 2015-12-10 | 2019-01-10 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病の治療方法 |
CN105384702B (zh) * | 2015-12-11 | 2018-04-10 | 浙江大学 | 三取代均三嗪类化合物及其制备方法 |
CN105503754B (zh) * | 2015-12-11 | 2017-11-17 | 浙江大学 | 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用 |
CN105399695B (zh) * | 2015-12-11 | 2019-04-19 | 浙江大学 | 三嗪类化合物及其制备方法和用途 |
US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
WO2017160569A1 (en) | 2016-03-14 | 2017-09-21 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
AU2017237929B2 (en) | 2016-03-25 | 2021-04-15 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | CANCER TREATMENT METHOD USING A COMBINATION OF DNA DAMAGING AGENTS AND DNA-PK INHIBITORS |
US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
US10968227B2 (en) * | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CN108239071B (zh) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
FR3064275B1 (fr) | 2017-03-21 | 2019-06-07 | Arkema France | Procede de chauffage et/ou climatisation d'un vehicule |
CA3063300A1 (en) | 2017-05-30 | 2018-12-06 | Basf Se | Pyridine and pyrazine compounds |
SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
CN110582489B (zh) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
US10329282B2 (en) | 2017-06-30 | 2019-06-25 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
EP3676264A1 (en) * | 2017-08-28 | 2020-07-08 | Acurastem Inc. | Pikfyve kinase inhibitors |
CN111683662B (zh) * | 2017-08-28 | 2024-04-02 | 陈志宏 | 取代嘧啶类化合物及其药物组合物和治疗方法 |
BR112020008015A2 (pt) | 2017-10-27 | 2020-10-27 | Theravance Biopharma R&D Ip, Llc | composto derivado da pirimidina como inibidor da quinase jak |
EP3672957A1 (en) * | 2017-11-23 | 2020-07-01 | BioMed X GmbH | Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors |
WO2019113311A1 (en) * | 2017-12-06 | 2019-06-13 | Ludwig Institute For Cancer Research Ltd | Methods of treating cancer with plk4 inhibitors |
CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
AU2019295632A1 (en) * | 2018-06-25 | 2020-11-26 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
CN112654625B (zh) | 2018-06-27 | 2024-08-06 | Ptc医疗公司 | 用于治疗亨廷顿氏病的杂环和杂芳基化合物 |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
US11155549B2 (en) | 2019-04-24 | 2021-10-26 | Theravance Biopharma R&D Ip, Llc | Ester and carbonate pyrimidine compounds as JAK kinase inhibitors |
WO2020219640A1 (en) | 2019-04-24 | 2020-10-29 | Theravance Biopharma R&D Ip, Llc | Pyrimidine jak inhibitors for the treatment of skin diseases |
KR20220042159A (ko) * | 2019-08-01 | 2022-04-04 | 인테그랄 바이오사이언스 피브이티. 엘티디. | 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도 |
WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
WO2021055621A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Plasma kallikrein inhibitors and uses thereof |
CN110483493A (zh) * | 2019-09-19 | 2019-11-22 | 广东工业大学 | 一种二唑类衍生物及其制备方法和应用 |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
CN117355523A (zh) * | 2021-03-17 | 2024-01-05 | 武田药品工业株式会社 | 血浆激肽释放酶的多环抑制剂 |
JP2024511466A (ja) * | 2021-03-26 | 2024-03-13 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Alk-5阻害剤及びその使用 |
MX2023013225A (es) | 2021-05-11 | 2024-01-15 | Oric Pharmaceuticals Inc | Inhibidores de la cinasa 4 similar a polo. |
AR126251A1 (es) | 2021-06-28 | 2023-10-04 | Blueprint Medicines Corp | Inhibidores de cdk2 |
KR102692529B1 (ko) * | 2021-07-01 | 2024-08-08 | 한국원자력의학원 | Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물 |
CN116354938B (zh) * | 2021-12-28 | 2024-02-20 | 沈阳药科大学 | 一类喹唑啉衍生物与其类似物的制备方法及应用 |
CN114276302B (zh) * | 2022-01-11 | 2023-07-25 | 山东百启生物医药有限公司 | 一种制备2,4-二氨基喹唑啉衍生物的方法 |
WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
CN115403568B (zh) * | 2022-09-21 | 2023-09-29 | 中山大学 | 一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用 |
CN117736198A (zh) * | 2022-09-21 | 2024-03-22 | 科辉智药生物科技(深圳)有限公司 | 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US18436A (en) * | 1857-10-20 | And saml | ||
US3133081A (en) | 1964-05-12 | J-aminoindazole derivatives | ||
US2585906A (en) | 1952-02-12 | Quaternary salts of pyrimdjines | ||
US3935183A (en) | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
DE2458965C3 (de) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
DOP1981004033A (es) | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
SE8102194L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
SE8102193L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
JPS58124773A (ja) | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | 5−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
EP0136976A3 (de) | 1983-08-23 | 1985-05-15 | Ciba-Geigy Ag | Verwendung von Phenylpyrimidinen als Pflanzenregulatoren |
DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
JPH0532662A (ja) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5597920A (en) | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
JPH0665237A (ja) * | 1992-05-07 | 1994-03-08 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
PT672042E (pt) | 1993-10-01 | 2006-08-31 | Novartis Ag | Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao |
WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
CA2230896A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
JPH10130150A (ja) | 1996-09-05 | 1998-05-19 | Dainippon Pharmaceut Co Ltd | 酢酸アミド誘導体からなる医薬 |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
DE69732780T2 (de) | 1996-10-02 | 2006-04-06 | Novartis Ag | Pyrimiderivate und verfahren zu ihrer herstellung |
JP2001506974A (ja) | 1996-10-11 | 2001-05-29 | ワーナー―ランバート・コンパニー | インターロイキン―1β変換酵素のアスパルテートエステル阻害剤 |
JP4439111B2 (ja) | 1997-10-10 | 2010-03-24 | サイトビア インコーポレイテッド | ジペプチドのアポトーシスインヒビターおよびそれらの使用 |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
JP2000026421A (ja) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
DE69909756D1 (de) | 1998-02-17 | 2003-08-28 | Tularik Inc | Antivirale pyrimidinderivate |
AU755273B2 (en) | 1998-03-16 | 2002-12-05 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
OA12147A (en) | 1998-06-02 | 2006-05-05 | Osi Pharm Inc | PyrroloÄ2,3dÜpyrimidine compositions and their use. |
JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | グリコーゲンシンターゼキナーゼ3のインヒビター |
WO2000003901A1 (de) * | 1998-07-16 | 2000-01-27 | Continental Teves Ag & Co. Ohg | Verfahren und vorrichtung zum ermitteln von kritischen fahrzuständen bei im fahrbetrieb befindlichen fahrzeugen |
EP1105394A1 (en) | 1998-08-21 | 2001-06-13 | Du Pont Pharmaceuticals Company | ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
NZ510434A (en) * | 1998-10-08 | 2003-10-31 | Astrazeneca Ab | Heterocylic substituted quinazoline derivatives useful as VEGF inhibitors |
GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
AP2001002225A0 (en) | 1999-01-13 | 2001-09-30 | Warner Lambert Co | 1-heterocycle substituted diarylamines. |
CN1221262C (zh) | 1999-03-30 | 2005-10-05 | 诺瓦提斯公司 | 治疗炎性疾病的酞嗪衍生物 |
EP1185528A4 (en) * | 1999-06-17 | 2003-03-26 | Shionogi Biores Corp | INHIBITORS OF IL-12 PRODUCTION |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001012621A1 (en) | 1999-08-13 | 2001-02-22 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
DE60039059D1 (de) | 1999-10-07 | 2008-07-10 | Amgen Inc | Triazin-kinase-hemmer |
AP2002002530A0 (en) | 1999-11-30 | 2002-06-30 | Pfizer Prod Inc | 2,4 diaminopyrimidine compounds useful as immunosuppressants. |
EP1246623B1 (en) | 1999-12-02 | 2006-08-09 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
US6376489B1 (en) | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
MY125768A (en) | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
WO2001057022A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
IL152022A0 (en) | 2000-04-03 | 2003-04-10 | Vertex Pharma | Compounds useful as protease inhibitors and pharmaceutical compositions containing the same |
AU2001249865A1 (en) | 2000-04-18 | 2001-10-30 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
JP3890184B2 (ja) * | 2000-05-15 | 2007-03-07 | Necパーソナルプロダクツ株式会社 | 電源装置及びその電力制御方法、情報処理機器 |
RU2283311C2 (ru) | 2000-06-28 | 2006-09-10 | Астразенека Аб | Замещенные производные хиназолина и их применение в качестве ингибиторов |
IL154016A0 (en) | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
WO2002022603A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ATE335737T1 (de) | 2000-09-15 | 2006-09-15 | Vertex Pharma | Isoxazole und ihre verwendung als erk-inhibitoren |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
BR0114020A (pt) | 2000-09-20 | 2003-07-22 | Merck Patent Gmbh | 4-amino-quinazolinas |
US6641579B1 (en) | 2000-09-29 | 2003-11-04 | Spectrasonics Imaging, Inc. | Apparatus and method for ablating cardiac tissue |
DE10061863A1 (de) | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
WO2002047690A1 (en) | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
PT1345922E (pt) | 2000-12-21 | 2006-09-29 | Vertex Pharma | Compostos de pirazole uteis como inibidores de proteina-quinase |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
MXPA03008888A (es) | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
WO2002083667A2 (en) | 2001-04-13 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
AU2002305205A1 (en) | 2001-04-20 | 2002-11-05 | Jingrong Cao | 9-deazaguanine derivatives as inhibitors of gsk-3 |
AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
WO2002102800A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
ATE337312T1 (de) | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
US6569499B2 (en) | 2001-10-02 | 2003-05-27 | Xerox Corporation | Apparatus and method for coating photoreceptor substrates |
AU2002364536B2 (en) | 2001-12-07 | 2008-10-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
US7179826B2 (en) | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
EP1485380B1 (en) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
WO2003078423A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Compositions useful as inhibitors of protein kinases |
AU2003220299A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
US20030207873A1 (en) | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
AU2003247959B2 (en) | 2002-07-09 | 2010-07-29 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
CN1319968C (zh) | 2002-08-02 | 2007-06-06 | 沃泰克斯药物股份有限公司 | 用作gsk-3的抑制剂的吡唑组合物 |
EP2099787B1 (en) | 2006-12-19 | 2010-07-21 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines useful as inhibitors of protein kinases |
-
2001
- 2001-12-19 PT PT01271061T patent/PT1345922E/pt unknown
- 2001-12-19 DE DE60119775T patent/DE60119775T2/de not_active Expired - Lifetime
- 2001-12-19 DE DE60119774T patent/DE60119774T2/de not_active Expired - Lifetime
- 2001-12-19 PL PL363246A patent/PL210066B1/pl unknown
- 2001-12-19 AT AT01273861T patent/ATE354573T1/de active
- 2001-12-19 EP EP10184271A patent/EP2264028A1/en not_active Withdrawn
- 2001-12-19 KR KR1020037008427A patent/KR100875091B1/ko not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/049401 patent/WO2002057259A2/en active Application Filing
- 2001-12-19 CN CNB018221025A patent/CN100436452C/zh not_active Expired - Fee Related
- 2001-12-19 PL PL363244A patent/PL210414B1/pl not_active IP Right Cessation
- 2001-12-19 IL IL15636801A patent/IL156368A0/xx not_active IP Right Cessation
- 2001-12-19 NZ NZ526468A patent/NZ526468A/en not_active IP Right Cessation
- 2001-12-19 SI SI200130656T patent/SI1353916T1/sl unknown
- 2001-12-19 NZ NZ526470A patent/NZ526470A/xx not_active IP Right Cessation
- 2001-12-19 ES ES01994323T patent/ES2272567T3/es not_active Expired - Lifetime
- 2001-12-19 SI SI200130722T patent/SI1355905T1/sl unknown
- 2001-12-19 AU AU2001297619A patent/AU2001297619B2/en not_active Ceased
- 2001-12-19 MX MXPA03005610A patent/MXPA03005610A/es active IP Right Grant
- 2001-12-19 AT AT01993360T patent/ATE326461T1/de active
- 2001-12-19 CA CA002432799A patent/CA2432799C/en not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005607A patent/MXPA03005607A/es active IP Right Grant
- 2001-12-19 NZ NZ526469A patent/NZ526469A/en not_active IP Right Cessation
- 2001-12-19 CA CA002432223A patent/CA2432223C/en not_active Expired - Fee Related
- 2001-12-19 HU HU0400908A patent/HUP0400908A3/hu unknown
- 2001-12-19 CN CNA018221033A patent/CN1486310A/zh active Pending
- 2001-12-19 NZ NZ526471A patent/NZ526471A/en not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/049139 patent/WO2002066461A1/en active IP Right Grant
- 2001-12-19 PT PT01273861T patent/PT1355905E/pt unknown
- 2001-12-19 JP JP2002565976A patent/JP2004518743A/ja active Pending
- 2001-12-19 NZ NZ526473A patent/NZ526473A/en not_active IP Right Cessation
- 2001-12-19 HU HU0400639A patent/HUP0400639A3/hu unknown
- 2001-12-19 DE DE60123283T patent/DE60123283T2/de not_active Expired - Lifetime
- 2001-12-19 KR KR1020037008385A patent/KR100889246B1/ko not_active IP Right Cessation
- 2001-12-19 EP EP01273861A patent/EP1355905B1/en not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/051031 patent/WO2002062789A1/en active IP Right Grant
- 2001-12-19 AT AT01985059T patent/ATE326460T1/de active
- 2001-12-19 MX MXPA03005606A patent/MXPA03005606A/es active IP Right Grant
- 2001-12-19 CA CA002432222A patent/CA2432222C/en not_active Expired - Fee Related
- 2001-12-19 AT AT01994510T patent/ATE326462T1/de active
- 2001-12-19 US US10/026,966 patent/US20030105090A1/en not_active Abandoned
- 2001-12-19 ES ES06011799T patent/ES2375491T3/es not_active Expired - Lifetime
- 2001-12-19 US US10/026,975 patent/US6653300B2/en not_active Expired - Fee Related
- 2001-12-19 JP JP2002567928A patent/JP4234435B2/ja not_active Expired - Fee Related
- 2001-12-19 CN CNB01822105XA patent/CN100406454C/zh not_active Expired - Fee Related
- 2001-12-19 DK DK01994323T patent/DK1353916T3/da active
- 2001-12-19 AU AU2002255452A patent/AU2002255452B2/en not_active Ceased
- 2001-12-19 DK DK01273861T patent/DK1355905T3/da active
- 2001-12-19 AP APAP/P/2003/002816A patent/AP1588A/en active
- 2001-12-19 CA CA002432131A patent/CA2432131C/en not_active Expired - Fee Related
- 2001-12-19 AU AU2002234047A patent/AU2002234047A1/en not_active Abandoned
- 2001-12-19 WO PCT/US2001/049140 patent/WO2002050065A2/en active IP Right Grant
- 2001-12-19 RU RU2003122209/04A patent/RU2355688C2/ru not_active IP Right Cessation
- 2001-12-19 DE DE60126828T patent/DE60126828T2/de not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/051120 patent/WO2002059111A2/en active IP Right Grant
- 2001-12-19 JP JP2002551561A patent/JP4160389B2/ja not_active Expired - Fee Related
- 2001-12-19 EP EP01993360A patent/EP1345926B1/en not_active Expired - Lifetime
- 2001-12-19 BR BR0116493-7A patent/BR0116493A/pt not_active IP Right Cessation
- 2001-12-19 US US10/027,001 patent/US6653301B2/en not_active Expired - Fee Related
- 2001-12-19 EP EP06011799A patent/EP1702920B1/en not_active Expired - Lifetime
- 2001-12-19 NZ NZ526472A patent/NZ526472A/en not_active IP Right Cessation
- 2001-12-19 EP EP01271061A patent/EP1345922B1/en not_active Expired - Lifetime
- 2001-12-19 HU HU0400842A patent/HUP0400842A2/hu unknown
- 2001-12-19 ES ES01271061T patent/ES2266095T3/es not_active Expired - Lifetime
- 2001-12-19 DE DE60119776T patent/DE60119776T2/de not_active Expired - Lifetime
- 2001-12-19 DK DK01271061T patent/DK1345922T3/da active
- 2001-12-19 ES ES01993360T patent/ES2265450T3/es not_active Expired - Lifetime
- 2001-12-19 US US10/026,992 patent/US7625913B2/en not_active Expired - Fee Related
- 2001-12-19 JP JP2002557938A patent/JP4210520B2/ja not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008409A patent/KR100909665B1/ko not_active IP Right Cessation
- 2001-12-19 CA CA002432129A patent/CA2432129C/en not_active Expired - Fee Related
- 2001-12-19 IL IL15640701A patent/IL156407A0/xx not_active IP Right Cessation
- 2001-12-19 AT AT01994323T patent/ATE340172T1/de active
- 2001-12-19 AP APAP/P/2003/002825A patent/AP2003002825A0/en unknown
- 2001-12-19 MX MXPA03005609A patent/MXPA03005609A/es active IP Right Grant
- 2001-12-19 WO PCT/US2001/050312 patent/WO2002068415A1/en active IP Right Grant
- 2001-12-19 KR KR1020037008387A patent/KR100843114B1/ko not_active IP Right Cessation
- 2001-12-19 PT PT01994323T patent/PT1353916E/pt unknown
- 2001-12-19 IL IL15640801A patent/IL156408A0/xx unknown
- 2001-12-19 CN CNB018221351A patent/CN100408573C/zh not_active Expired - Fee Related
- 2001-12-19 CA CA2432303A patent/CA2432303C/en not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005608A patent/MXPA03005608A/es not_active Application Discontinuation
- 2001-12-19 JP JP2002563142A patent/JP4160395B2/ja not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005605A patent/MXPA03005605A/es active IP Right Grant
- 2001-12-19 CN CN2011101042845A patent/CN102250071A/zh active Pending
- 2001-12-19 EP EP01985059A patent/EP1345925B1/en not_active Expired - Lifetime
- 2001-12-19 DE DE60120219T patent/DE60120219T2/de not_active Expired - Lifetime
- 2001-12-19 IL IL15638901A patent/IL156389A0/xx active IP Right Grant
- 2001-12-19 ES ES01985059T patent/ES2265446T3/es not_active Expired - Lifetime
- 2001-12-19 ES ES01994510T patent/ES2265452T3/es not_active Expired - Lifetime
- 2001-12-19 AT AT06011799T patent/ATE528303T1/de not_active IP Right Cessation
- 2001-12-19 EP EP01994510A patent/EP1345927B1/en not_active Expired - Lifetime
- 2001-12-19 US US10/026,967 patent/US6989385B2/en not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008397A patent/KR100947185B1/ko not_active IP Right Cessation
- 2001-12-19 ES ES01273861T patent/ES2280313T3/es not_active Expired - Lifetime
- 2001-12-19 BR BR0116411-2A patent/BR0116411A/pt not_active IP Right Cessation
- 2001-12-19 CN CNB01822136XA patent/CN100340555C/zh not_active Expired - Fee Related
- 2001-12-19 HU HU0400641A patent/HUP0400641A3/hu unknown
- 2001-12-19 IL IL15636901A patent/IL156369A0/xx active IP Right Grant
- 2001-12-19 HU HU0400638A patent/HUP0400638A2/hu unknown
- 2001-12-19 EP EP01994323A patent/EP1353916B1/en not_active Expired - Lifetime
- 2001-12-19 KR KR10-2003-7008415A patent/KR20030061858A/ko active IP Right Grant
- 2001-12-19 US US10/025,164 patent/US6664247B2/en not_active Expired - Fee Related
- 2001-12-19 AT AT01271061T patent/ATE327989T1/de active
- 2001-12-19 JP JP2002559413A patent/JP4160392B2/ja not_active Expired - Fee Related
- 2001-12-20 AR ARP010105962A patent/AR042169A1/es active IP Right Grant
- 2001-12-20 CA CA002432132A patent/CA2432132C/en not_active Expired - Fee Related
- 2001-12-20 CA CA002432872A patent/CA2432872C/en not_active Expired - Fee Related
- 2001-12-20 KR KR10-2003-7008364A patent/KR20030061463A/ko active IP Right Grant
- 2001-12-20 EP EP01994347A patent/EP1345929B1/en not_active Expired - Lifetime
- 2001-12-20 MX MXPA03005611A patent/MXPA03005611A/es unknown
- 2001-12-20 WO PCT/US2001/049594 patent/WO2002059112A2/en active IP Right Grant
- 2001-12-20 AR ARP010105961A patent/AR042398A1/es unknown
- 2001-12-20 AU AU2002231166A patent/AU2002231166B2/en not_active Ceased
- 2001-12-20 EP EP01991439A patent/EP1345928B1/en not_active Expired - Lifetime
- 2001-12-20 AR ARP010105963A patent/AR040925A1/es active IP Right Grant
- 2001-12-20 AR ARP010105960A patent/AR042397A1/es active IP Right Grant
- 2001-12-20 AT AT01991439T patent/ATE353890T1/de not_active IP Right Cessation
- 2001-12-20 US US10/034,683 patent/US6656939B2/en not_active Expired - Fee Related
- 2001-12-20 WO PCT/US2001/049585 patent/WO2002050066A2/en active IP Right Grant
- 2001-12-20 DE DE60126658T patent/DE60126658T2/de not_active Expired - Lifetime
- 2001-12-20 MX MXPA03005612A patent/MXPA03005612A/es not_active Application Discontinuation
- 2001-12-20 US US10/034,019 patent/US6727251B2/en not_active Expired - Fee Related
- 2001-12-20 JP JP2002551562A patent/JP2004516292A/ja active Pending
- 2001-12-20 NZ NZ526474A patent/NZ526474A/en unknown
- 2001-12-20 JP JP2002559414A patent/JP2004517927A/ja active Pending
- 2001-12-20 NZ NZ526475A patent/NZ526475A/en unknown
- 2001-12-20 KR KR10-2003-7008366A patent/KR20030061464A/ko not_active Application Discontinuation
- 2001-12-20 AU AU3116602A patent/AU3116602A/xx active Pending
- 2001-12-20 DE DE60119777T patent/DE60119777T2/de not_active Expired - Lifetime
- 2001-12-20 AU AU2002246754A patent/AU2002246754B2/en not_active Ceased
- 2001-12-20 AT AT01994347T patent/ATE326463T1/de not_active IP Right Cessation
- 2001-12-21 MY MYPI20015823A patent/MY140377A/en unknown
- 2001-12-25 TW TW090131846A patent/TWI290551B/zh not_active IP Right Cessation
- 2001-12-25 TW TW095139649A patent/TWI313269B/zh not_active IP Right Cessation
-
2003
- 2003-06-10 IL IL156369A patent/IL156369A/en not_active IP Right Cessation
- 2003-06-11 IL IL156389A patent/IL156389A/en not_active IP Right Cessation
- 2003-06-12 NO NO20032670A patent/NO328537B1/no not_active IP Right Cessation
- 2003-06-12 NO NO20032671A patent/NO20032671L/no not_active Application Discontinuation
- 2003-06-13 NO NO20032703A patent/NO328501B1/no not_active IP Right Cessation
- 2003-06-13 NO NO20032704A patent/NO330527B1/no not_active IP Right Cessation
- 2003-06-16 NO NO20032736A patent/NO20032736L/no unknown
- 2003-08-01 US US10/632,428 patent/US7531536B2/en not_active Expired - Fee Related
- 2003-11-25 US US10/722,374 patent/US20040157893A1/en not_active Abandoned
- 2003-12-15 US US10/736,426 patent/US7087603B2/en not_active Expired - Fee Related
-
2004
- 2004-02-10 US US10/775,699 patent/US7427681B2/en not_active Expired - Fee Related
- 2004-02-12 HK HK04100960A patent/HK1059776A1/xx not_active IP Right Cessation
- 2004-03-15 HK HK04101883A patent/HK1060347A1/xx not_active IP Right Cessation
- 2004-03-15 HK HK04101882A patent/HK1060346A1/xx not_active IP Right Cessation
- 2004-03-16 HK HK04101940A patent/HK1060557A1/xx not_active IP Right Cessation
- 2004-03-16 HK HK04101941A patent/HK1062433A1/xx not_active IP Right Cessation
- 2004-03-17 HK HK04101996A patent/HK1060349A1/xx not_active IP Right Cessation
- 2004-03-22 HK HK04102099A patent/HK1061389A1/xx not_active IP Right Cessation
- 2004-07-27 HK HK04105510.6A patent/HK1062565A1/xx not_active IP Right Cessation
- 2004-12-17 JP JP2004366925A patent/JP2005097322A/ja not_active Withdrawn
-
2006
- 2006-03-21 AU AU2006201267A patent/AU2006201267B2/en not_active Ceased
- 2006-12-20 CY CY20061101823T patent/CY1106297T1/el unknown
-
2008
- 2008-04-01 JP JP2008095584A patent/JP2008260767A/ja not_active Withdrawn
- 2008-04-01 JP JP2008095581A patent/JP2008189682A/ja not_active Withdrawn
- 2008-04-03 JP JP2008097620A patent/JP2008222719A/ja active Pending
- 2008-04-04 JP JP2008098506A patent/JP2008189687A/ja active Pending
- 2008-04-25 US US12/109,598 patent/US8304414B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2008121723A patent/JP2008201808A/ja active Pending
- 2008-05-07 JP JP2008121727A patent/JP2008247921A/ja active Pending
- 2008-05-07 JP JP2008121724A patent/JP2008247920A/ja active Pending
-
2009
- 2009-04-17 JP JP2009101481A patent/JP5249842B2/ja not_active Expired - Fee Related
- 2009-08-21 US US12/545,347 patent/US7982037B2/en not_active Expired - Fee Related
- 2009-09-14 JP JP2009212566A patent/JP2009286805A/ja not_active Withdrawn
-
2010
- 2010-12-07 IL IL209827A patent/IL209827A0/en unknown
-
2012
- 2012-09-28 US US13/631,488 patent/US8697698B2/en not_active Expired - Fee Related
-
2013
- 2013-07-19 JP JP2013150948A patent/JP2013213068A/ja active Pending
- 2013-12-24 US US14/139,889 patent/US20140187772A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL156369A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL154817A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL145757A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL145756A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL152451A0 (en) | 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same | |
HUP0301178A3 (en) | Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same | |
IL153123A0 (en) | N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same | |
HUP0303108A3 (en) | Substituted pyrazoles and pharmaceutical compositions containing them | |
IL177018A0 (en) | Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same | |
AU2001290257A1 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
AU2001290257A2 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
IL161616A0 (en) | Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
IL164209A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL166620A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL152490A0 (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
IL155196A0 (en) | Benzamide derivatives and pharmaceutical compositions containing the same | |
IL158300A0 (en) | Bisarylimidazol derivatives and pharmaceutical compositions containing the same | |
IL158044A0 (en) | Cyclopropylindole derivatives and pharmaceutical compositions containing the same | |
IL156812A0 (en) | Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same | |
IL150449A0 (en) | Aniline derivatives and pharmaceutical compositions containing the same | |
IL152846A0 (en) | Pyridazinone derivatives and pharmaceutical compositions containing the same | |
IL156813A0 (en) | Imidazolyl derivatives and pharmaceutical compositions containing the same | |
IL157740A0 (en) | Heterocyclic derivatives and pharmaceutical compositions containing the same | |
IL147214A0 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same | |
HUP0303184A3 (en) | Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them |